Last reviewed · How we verify

Oxycodone intravenously

Kuopio University Hospital · FDA-approved active Small molecule

Oxycodone binds to opioid receptors in the central nervous system to block pain signal transmission and produce analgesia.

Oxycodone binds to opioid receptors in the central nervous system to block pain signal transmission and produce analgesia. Used for Acute moderate to severe pain in hospitalized patients, Postoperative pain management.

At a glance

Generic nameOxycodone intravenously
Also known asoxycodoneIV
SponsorKuopio University Hospital
Drug classOpioid analgesic
TargetMu (μ) opioid receptor
ModalitySmall molecule
Therapeutic areaPain Management
PhaseFDA-approved

Mechanism of action

Oxycodone is a semi-synthetic opioid agonist that acts primarily on mu (μ) opioid receptors in the brain and spinal cord. By binding to these receptors, it inhibits the release of neurotransmitters involved in pain perception and modulates pain signaling pathways. The intravenous formulation provides rapid onset of action for acute pain management in hospital settings.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: